Cardiovascular

Latest News

  New Heart Failure Med Will be Priced 'Competitively'
New Heart Failure Med Will be Priced 'Competitively'

May 30th 2023

Inpefa (sotagliflozin) is in the SGLT inhibitor class recommended as first-line treatment for heart failure by the American Heart Association and other groups. Jardiance (empaglifozin), a competitor in that class, has a list price of $570.48 for a month's supply.

FDA Extends Evkeeza Indication to Include Young Children
FDA Extends Evkeeza Indication to Include Young Children

March 22nd 2023

FDA to Hold Advisory Committee Meeting on Onpattro for Heart Failure Indication
FDA to Hold Advisory Committee Meeting on Onpattro for Heart Failure Indication

February 22nd 2023

Study: Lower Rebates, and Lower Prices, Lead to Lower Patient Costs
Study: Lower Rebates, and Lower Prices, Lead to Lower Patient Costs

February 8th 2023

Study: Heart Failure Patients Could Save with Inflation Reduction Act
Study: Heart Failure Patients Could Save with Inflation Reduction Act

January 25th 2023

More News

© 2023 MJH Life Sciences

All rights reserved.